On November 26, 2024, Fosun Pharma conducted a share repurchase on the Hong Kong Stock Exchange, repurchasing a quantity of 117,000 H shares at a repurchase price ranging from HKD 13.96 to HKD 14.12 per share, totaling approximately HKD 1,641,884.4. The repurchased shares will be held as treasury shares and not cancelled. The repurchase authorization was approved on June 26, 2024, with a total authorization of 55,194,050 shares. This repurchase represented 1.1% of the issued shares on the day of authorization. Due to this repurchase, the number of issued shares of Fosun Pharma decreased from 546,011,000 shares to 545,894,000 shares, with treasury shares increasing to 6,046,500 shares. In accordance with the rules of the Hong Kong Stock Exchange, Fosun Pharma shall not issue new shares or sell treasury shares within 30 days after the repurchase, and the suspension period ends on December 26, 2024.

On November 26, 2024, Fosun Pharma conducted a share repurchase on the Hong Kong Stock Exchange, repurchasing a quantity of 117,000 H shares at a repurchase price ranging from HKD 13.96 to HKD 14.12 per share, totaling approximately HKD 1,641,884.4. The repurchased shares will be held as treasury shares and not cancelled. The repurchase authorization was approved on June 26, 2024, with a total authorization of 55,194,050 shares. This repurchase represented 1.1% of the issued shares on the day of authorization. Due to this repurchase, the number of issued shares of Fosun Pharma decreased from 546,011,000 shares to 545,894,000 shares, with treasury shares increasing to 6,046,500 shares. In accordance with the rules of the Hong Kong Stock Exchange, Fosun Pharma shall not issue new shares or sell treasury shares within 30 days after the repurchase, and the suspension period ends on December 26, 2024.